GBP/NZD initially dipped but recovered ground as investors awaited Bank of Englands next policy decision due later this week.

The Bank of England is widely expected to cut interest rates this Thursday but there is still some uncertainty around the ...

The 'pill penalty,' an unintended consequence of the IRA, has led to a disparity in investment for research and development ...

Below is Validea's guru fundamental report for MARATHON PETROLEUM CORP (MPC). Of the 22 guru strategies we follow, MPC rates highest using our Shareholder Yield Investor model based on the ...

A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...

Syria’s president has received a Republican member of Congress in the first visit to the country by American legislators since the ouster of former leader Bashar Assad DAMASCUS, Syria -- Syria ...

The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

A California biotech company has developed a new pill that could extend a dog’s life. After one year of the groundbreaking clinical trial, the pill cleared a major FDA hurdle. More than 1,000 ...

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients.

A new experimental GLP-1 drug, in pill form, could transform the weight loss drug boom. Eli Lilly's new experimental pill called orforglipron, helped patients shed weight and control blood sugar ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...